About Agilent Technologies, Inc.

Products from Agilent Technologies have a measurable effect on the scientific world. A leading maker of scientific testing equipment, Agilent supplies a slew of analytical and measurement instruments, including gas and liquid chromatographs, mass spectrometers, vacuum pumps, anatomic pathology workflows, and genetic and diagnostic instruments and tools. Its operations include products used in life sciences, chemical analysis, energy, and food, forensics, and environment. Agilent's customers include Bristol-Myers Squib Co., Dow Chemical, Merck, and the University of California, Davis.


Agilent operates through three business segments: life sciences and applied markets, diagnostics and genomics, and Agilent CrossLab.

The life sciences and applied markets business bring in about half of Agilent's revenue by providing instruments and software that customers use to identify, quantify, and analyze the physical and biological properties of substances and products.

Agilent CrossLab accounts for about a third of the company's revenue with its portfolio of consumables and services.

Diagnostics and genomics generates more than 15% of Agilent's revenue from reagents, instruments, microarrays, and synthetic RNA.


Geographic Reach

The US is Agilent's largest single geographic market, accounting for 40% of sales. China, the only other country Agilent reports separately, accounts for a fifth of sales. Other international operations provide the remainder of revenue. Agilent has manufacturing plants in Australia, China, Denmark, Germany, India, Italy, Japan, Malaysia, The Netherlands, Poland, Singapore, the UK, and the US.

Sales and Marketing

Agilent sells most of its products directly, although it also sells through resellers, distributors, e-commerce, and other channels. It also has a diverse customer base -- some 26,000 customers in the life sciences and applied markets business, about 49,000 Agilent CrossLab customers, and about 11,000 diagnostics and genomics customers. The company spends nearly $40 million a year on advertising.

Financial Performance

Agilent maintained its steady growth over several years with a 6% increase to about $4.5 billion in 2017 (ended October) from 2016, driven by stronger sales in each of the company's three segments.

The company said life sciences had solid growth in biotechnology while the applied side of the segment had growth in the chemical and energy, food and environmental markets. The diagnostics and pathology businesses drove revenue higher in diagnostics and genomics. In Agilent CrossLab, the biotechnology and pharmaceutical, chemical and energy, and food markets boosted sales. Foreign currency exchange rates reduced its overall earnings by a percentage point in 2017 from 2016.

Agilent posted about a 50% gain in net income, to about $684 million in 2017 from 2016. The company kept expenses to a lower percentage of sales in 2017 compared to 2016, producing the profit leap.

Agilent has about $2.8 billion cash on hand at the end of 2017, compared to about $2.3 billion the year before.


Agilent has identified product and geographic markets primed for growth while it relies on the slower-growing chemical and energy and environment and forensics markets, where it's the market leader, for sustaining revenue. The company sees growth opportunities in food, pharmaceuticals, academic and government, and clinical diagnostics, areas where its market share lags the competition.

The company has invested about $1 billion on research and development in the past three years, which has resulted in several new product that have caught customers' attention. An example is the Agilent Ultivo LC/MS triple quadrupole mass spectromter introduced in 2017. The instrument is 70% smaller than the previous model while performing as well or better than bigger devices. The company said it would maintain a similar level of research investment in the next three years.

The company also looks outside for technologies. Acquisitions in 2016, 2017, and 2018 have helped Agilent expand its product lines for diagnostics, therapeutics, and genomics research. The purchases of Cobalt and Multiplicom have revved up Agilent's revenue in those areas.

Agilent continues to pursue opportunities in China and India, where combined revenue surpassed $1 billion for the first time. The company intends to leverage its high position in instrumentation to gain share in services and consumables in those markets. Overall, the Asia/Pacific region accounts for more than 35% of Agilent's revenue, surpassing the Americas and Europe.

The company has maintained control of costs, which, it says, should be aided by consolidating its company-wide financial reporting on one platform.

Mergers and Acquisitions

Agilent Technologies has been active in acquisitions in the past two or three years to add technologies to its portfolio.

In 2018 Agilent closed its acquisition of ProZyme, a provider of glycan reagents, kits, and standards. The deal fortifies Agilent in glycobiology, a fast-growing part of biopharma. Agilent also bought Ultra Scientific, a provider of chemical standards and certified reference materials. Taken together, the deals are part of Agilent's effort to provide customers with more workflow-specific consumables and tools.

Also in 2018 Agilent Technologies acquired Luxcel Biosciences, developer of real-time fluorescence plate-reader–based in vitro cell-assay kits. The deal expands Agilent's cell-analysis portfolio with Luxcel assay kits designed for ease-of-use and compatible with industry-standard plate readers.

In 2017 Agilent purchased Cobalt Light Systems, a provider of differentiated raman spectroscopic instruments, for more than $50 million in cash. The acquisition of puts immediately slots Agilent into the fast-growing spectroscopy segment.

Another 2017 acquisition of Multiplicom N.V., added to Agilent's genomics portfolio with sequencing workflow capabilities from Multiplicom's molecular-diagnostics kits.

Agilent bought iLab Solutions, a provider of cloud-based services for core laboratory management, for $26 million in 2016. The deal gave Agilent an offering for managing laboratory time and work.

In 2016 Agilent bought a 48% stake in Lasergen Inc., a biotechnology company that develops sequencing technology, to collaborate on sequencing workflow for clinical applications, based on Lasergen's Lightning Terminators sequencing chemistry.

- Show Less + Show Full Description

Company News and Press Releases

- Show Less + Show More News and Press Releases

Agilent Technologies, Inc.

5301 Stevens Creek Blvd
Santa Clara, CA 95051-7201
Phone: 1 (408) 345-8886


  • Employer Type: Public
  • Stock Symbol: A
  • Stock Exchange: NYSE
  • President and CEO: Michael R. McMullen
  • SVP and CFO: Didier Hirsch
  • President and CEO: Michael R. McMullen
  • 2017 Employees: 13,500

Major Office Locations

  • Santa Clara, CA

Other Locations

  • Tempe, AZ
  • Carpinteria, CA
  • Folsom, CA
  • La Jolla, CA
  • Newark, CA
  • Roseville, CA
  • Westlake Village, CA
  • Aurora, CO
  • Boulder, CO
  • Colorado Springs, CO
  • Wilmington, DE
  • Arlington Heights, IL
  • Chicago, IL
  • Andover, MA
  • Chicopee, MA
  • Lexington, MA
  • Budd Lake, NJ
  • New York, NY
  • North Kingstown, RI
  • Cedar Creek, TX
  • Everett, WA
  • Liberty Lake, WA
  • Renton, WA
  • Madison, WI
  • Barueri, Brazil
  • Itapevi, Brazil
  • Nepean, Canada
  • Montpellier, France
  • Venissieux, France
  • Chiyoda-Ku, Japan
  • Kobe, Japan
  • Minato-Ku, Japan
  • Osaka, Japan
  • Rolle, Switzerland
- Show Less + Show More